Specific anti-nuclear antibodies in systemic sclerosis patients with and without skin involvement: an extended methodological approach
Authors:
- Jens T. Van PraetJPJens T. Van Praet
- Katleen Van SteendamKSKatleen Van Steendam
- Vanessa SmithVSVanessa Smith
- Georges De BruyneGBGeorges De Bruyne
- Tsuneyo MimoriTMTsuneyo Mimori
- Carolien BonroyCBCarolien Bonroy
- Dirk ElewautDEDirk Elewaut
- Dieter DeforceDDDieter Deforce
- Filip De KeyserFKFilip De Keyser
- 17 February 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 50 (7) , 1302-1309
Abstract
To determine how sensitively SSc-associated ANAs are detected by a standard identification algorithm compared with an extensive panel of ANA identification assays, and to assess the distribution of SSc-associated ANAs and SSc organ system involvement in patients without skin involvement (limited SSc). Serum samples from 145 consecutive monocentric SSc patients fulfilling LeRoy and Medgser's criteria for early SSc were studied. ANAs were detected by IIF on HEp-2000 cells and identified by western blotting, protein radio-immunoprecipitation, RNA immunoprecipitation and line immunoassay (LIA). SSc organ involvement was assessed according to a modification of Medsger's disease severity scale. At least one specific ANA reactivity was present in 88% of the patients. The standard algorithm (IIF and LIA) found at least one specific ANA in 74% of the patients. The main reactivities missed by this algorithm were anti-RNA polymerase III, anti-PM/Scl and anti-Th/To. Eighty-three percent of the patients with limited SSc had at least one ANA. ACAs and anti-Th/To antibodies were significantly associated with limited SSc, whereas anti-topoisomerase I and anti-RNA polymerase III were observed less frequently. SSc organ system involvement was present in 63% of the patients with limited SSc, most of whom had lung involvement. Standard algorithms for ANA identification lack sensitivity for the detection of SSc-associated ANA and should be supplemented with additional assays, especially in a clinical environment that has particular interest in SSc. The spectrum of SSc-associated ANA differs according to the presence or absence of skin involvement.Keywords
This publication has 18 references indexed in Scilit:
- Reliability of the qualitative and semiquantitative nailfold videocapillaroscopy assessment in a systemic sclerosis cohort: a two-centre studyAnnals of the Rheumatic Diseases, 2010
- Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: A twenty‐year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosisArthritis & Rheumatism, 2008
- Aseptic meningitis in mixed connective tissue disease: cytokine and anti-U1RNP antibodies in cerebrospinal fluids from two different casesModern Rheumatology, 2008
- Mechanisms and consequences of fibrosis in systemic sclerosisNature Clinical Practice Rheumatology, 2006
- Autoantibodies in Systemic SclerosisSeminars in Arthritis and Rheumatism, 2005
- The association of antinuclear antibodies with organ involvement and survival in systemic sclerosisRheumatology, 2003
- A comparison between anti‐Th/To– and anticentromere antibody–positive systemic sclerosis patients with limited cutaneous involvementArthritis & Rheumatism, 2003
- Detection and identification of antinuclear antibodies (ANA) in a large and consecutive cohort of serum samples referred for ANA testingAnnals of the Rheumatic Diseases, 2001
- Clinical and Prognostic Associations Based on Serum Antinuclear Antibodies in Japanese Patients with Systemic SclerosisArthritis & Rheumatism, 1994
- Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosisArthritis & Rheumatism, 1988